Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Gene Therapy
100%
SCID Mice
100%
Multiple Treatments
100%
Adenovirus
100%
Adenoviral
100%
Human Pancreatic Cancer Cells
100%
Treatment Cycle
100%
Ablating
100%
Liposome-encapsulated
100%
TK Gene
100%
Ganciclovir
66%
Cholesterol
33%
Liposomes
33%
4-cycle
33%
Adenovector
33%
DOTAP
33%
Adenoviral Gene Therapy
33%
Cell-Associated
16%
Promising Strategies
16%
Cancer Therapy
16%
High Titer
16%
Diabetic
16%
PANC-1
16%
Humoral Immune Response
16%
Neutralizing Antibodies
16%
Survival Time
16%
Thymidine Kinase
16%
Serotype 5
16%
Islet Cells
16%
Minimal Residual
16%
Number of Cycles
16%
Transient Gene Expression
16%
Insulin Promoter
16%
Immunoneutralization
16%
Liposomal Encapsulation
16%
Neutralizing Effect
16%
Residual Cancer Burden
16%
3-cycle
16%
PANC-1 Cells
16%
Can Shields
16%
Medicine and Dentistry
Liposome
100%
Gene Therapy
100%
Cancer Cell
100%
Pancreas Cancer
100%
SCID Mouse
100%
Adenoviridae
100%
Multiple Cycle Treatment
100%
Ganciclovir
66%
Adenovirus Vector
33%
1,2 Dioleoyl 3 Trimethylammoniopropane
33%
Neoplasm
16%
Promoter Region
16%
Serotype
16%
Diabetes Mellitus
16%
Cancer Therapy
16%
Humoral Immunity
16%
Survival Time
16%
Thymidine Kinase
16%
Transient Expression
16%
Neutralization
16%
Neutralizing Antibody
16%
Immunoneutralization
16%
Pharmacology, Toxicology and Pharmaceutical Science
Liposome
100%
Pancreas Cancer
100%
SCID Mouse
100%
Adenoviridae
100%
Multiple Cycle Treatment
100%
Ganciclovir
66%
Adenovirus Vector
33%
1,2 Dioleoyl 3 Trimethylammoniopropane
33%
Malignant Neoplasm
16%
Neoplasm
16%
Diabetes Mellitus
16%
C57BL 6 Mouse
16%
Survival Time
16%
Thymidine Kinase
16%
Neutralizing Antibody
16%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Adenoviridae
100%
Gene Therapy
100%
SCID Mouse
100%
Multiple Cycle Treatment
100%
Adenovirus Vector
33%
Tumor Volume
16%
Promoter Region
16%
Serotype
16%
Humoral Immunity
16%
Titer
16%
C57BL 6 Mouse
16%
Survival Time
16%
Thymidine Kinase
16%
Transient Expression
16%
Neutralizing Antibody
16%
Immunology and Microbiology
Cancer Cell
100%
SCID Mouse
100%
Adenoviridae
100%
Multiple Cycle Treatment
100%
Adenovirus Vector
33%
Promoter Region
16%
Insulin
16%
Serotype
16%
Titer
16%
Humoral Immunity
16%
C57BL 6 Mouse
16%
Neutralizing Antibody
16%
Neutralization
16%
Tumor Volume
16%
Survival Time
16%
Transient Expression
16%